Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of November 2015. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The filing serves to incorporate by reference a press release dated November 8, 2015, attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific financial data. No values are disclosed for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts solely as a conduit for the attached press release.
Material Changes
The filing text does not contain comparative financial data or descriptions of material changes versus prior periods. Any material changes would be detailed in the attached Exhibit 99.1 press release, the content of which is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or details on contingencies and unusual items. These elements are presumed to be contained within the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Verify the actual content of the press release dated November 8, 2015 (Exhibit 99.1), as the filing itself contains no substantive news.
- Confirm the registrant name is Galapagos NV, noting a discrepancy with the metadata label "Lakefront Biotherapeutics NV."
- Check for subsequent filings or updates regarding the specific announcement made on November 8, 2015.